티디에스팜

464280KOSDAQ

69.8 / 100

Reference Date: 2026-09-08

Financial Score28.5 / 40

News Sentiment21.3 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Rose 9.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

TDS Pharm specializes in the development and manufacturing of transdermal drug delivery systems (TDDS), holding a leading position in the Korean market with key products like Cataplasma and Plaster. The company aims to grow into a global pharmaceutical firm by expanding its portfolio to include patches targeting dementia, asthma, nicotine addiction, and other therapeutic areas.

Number of Employees

111people

Average Salary

32.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.59Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.76Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

10.52Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

0.38Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20254.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.4% (1-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.9% (1-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.3% (declining, 2yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
티디에스팜, 상반기 매출 161억원,,,전년比 48% 증가
티디에스팜의 상반기 매출이 전년 대비 48% 증가하며 온라인 및 의약외품 사업 확장과 제품 단가 인상으로 수익성이 크게 개선되었다.

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 5,870Won52-week high 10,50052-week low 4,525

1-month return5.0Point

1m +9.72% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-09-07
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-09-07
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-09-07
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-09-07
Neutral반기보고서 (2026.06)2026-08-14